Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients

Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks

Data shared in oral presentation at AASLD The Liver Meeting® and simultaneously published in The New England Journal of Medicine

Results demonstrate how Alnylam's RNAi platform and strategic partnerships can expand therapeutic opportunities and create long-term value beyond its wholly owned pipeline

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that were sustained through week 36. The Regeneron data were published by The New England Journal of Medicine and simultaneously presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026.

CIDEBsiRNA is an investigational RNAi therapeutic (also known as an siRNA therapeutic). Scientists at the Regeneron Genetics Center® (RGC) analyzed genetic data to discover and/or validate genetic variants in the CIDEB and other genes that are associated with liver disease risk. Building on these findings, Regeneron collaborated with Alnylam to generate an siRNA targeting CIDEB. Since 2023 when the candidate was identified, Regeneron has led development and holds exclusive rights for commercialization of CIDEBsiRNA. Alnylam is eligible to receive development milestones and tiered, double-digit royalties up to 20%.